Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Videos|November 16, 2026

FDA's Rare Disease Framework Aims for Consistency Across Review Divisions, Says Former FDA Reviewer Paz Vellanki

In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.

Rare disease programs often cannot enroll enough patients to run the two adequate and well-controlled trials that have long anchored FDA approvals. That puts more weight on what sponsors can offer alongside a single trial, and on whether reviewers across the agency will weigh that evidence the same way.

Paz Vellanki, MD, PhD, vice president of clinical development, oncology, at Precision for Medicine and a former supervisory associate director in FDA's Division of Oncology 2, addressed both questions in the second part of a two-part video interview with BioPharm International®. She also discussed what FDA's October 28, 2026, public meeting on the Rare Disease Framework Initiative suggested about the program's future.

"Historically, we've thought in basic drug development principles. Again, for more common diseases, we often thought about two clinical trials, two adequate and well-controlled clinical trials being necessary to support an approval for a product," Vellanki said. "We have seen a shift."

She said oncology moved first. "I'm coming from an oncology background, and for a long time, we have not required that there are two adequate and well-controlled trials that are necessary to support a drug approval," she said, adding that FDA has recently issued guidance that extends this approach to other disease areas.

Without a second trial, sponsors need one adequate and well-controlled trial plus confirmatory evidence. "And what does that confirmatory evidence look like? That could be looking at some non-clinical data. We've seen examples in the rare disease space where you're also looking at maybe natural history data and how that might support and provide confirmatory evidence to support a drug approval," Vellanki said.

Why does flexibility vary across FDA review divisions?

"FDA recognizes that it's very important for there to be increased consistency and predictability within FDA and across divisions." – Paz Vellanki, MD, PhD, vice president of clinical development, oncology, Precision for Medicine

FDA has said that rare disease flexibility has been applied unevenly across its review divisions. Vellanki said part of the reason is the review itself. "You have individual reviewers on a given application, and of course that introduces a human component. We all come with our different experiences, our different lenses in which we're viewing an application," she said.

She noted that the framework is an agency-wide effort spanning the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Center for Devices and Radiological Health. "One of the main pillars that they are focusing on is really to ensure that there is more predictability across these divisions," she said.

Vellanki said the October 28 meeting emphasized outside input, including from patients. According to Vellanki, Michael Davis, M.D., Ph.D., center director of FDA’s Center for Drug Evaluation and Research (CDER) indicated that new guidance could follow. "Maybe there are new internal processes or templates that might be used to help support consistency," she said.

Asked whether the framework will outlast current FDA leadership, Vellanki said, "That is certainly the hope." She pointed to the three hours of public comment at the October 28 meeting and the mix of industry and patient advocacy voices FDA is drawing in.

"FDA is doubling down, and they know that drug development for rare diseases is very important. And they're engaging the wider community, and I think this will help stand the test of time," she said.

FDA is accepting comments on the initiative through December 11, 2026, under docket FDA-2026-N-12214.

Check out the first part of this two-part interview here.

About the Speaker

Paz Vellanki, MD, PhD, vice president of clinical development, Precision for Medicine

Paz Vellanki joined Precision for Medicine after nearly seven years at FDA, where she worked in the Division of Oncology 2 from August 2019 to May 2026. She served as a medical officer, then as a clinical team lead, and from May 2024 as supervisory associate director. The division oversees drug development for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors, and rare diseases.


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.